Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Matsumoto T, Yamamoto Y, Kotaka M, Masuishi T, Tsuji Y, Shoji H, Hirata K, Tsuduki T, Makiyama A, Izawa N, Takahashi N, Tsuda M, Yasui H, Ohta T, Kito Y, Otsu S, Hironaka S, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K. Matsumoto T, et al. Among authors: hirata k. Target Oncol. 2024 Mar;19(2):181-190. doi: 10.1007/s11523-024-01043-2. Epub 2024 Mar 1. Target Oncol. 2024. PMID: 38427280 Free PMC article. Clinical Trial.
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K, Hamamoto Y, Ando M, Imamura CK, Yoshimura K, Yamazaki K, Hironaka S, Muro K. Hirata K, et al. BMC Cancer. 2020 Jun 12;20(1):548. doi: 10.1186/s12885-020-07047-1. BMC Cancer. 2020. PMID: 32532230 Free PMC article.
An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7).
Kawakami H, Hironaka S, Esaki T, Chayama K, Tsuda M, Sugimoto N, Kadowaki S, Makiyama A, Machida N, Hirano H, Hirata K, Hara H, Yabusaki H, Komatsu Y, Muro K. Kawakami H, et al. Among authors: hirata k. Cancers (Basel). 2021 Feb 15;13(4):805. doi: 10.3390/cancers13040805. Cancers (Basel). 2021. PMID: 33671871 Free PMC article.
WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study).
Shimozaki K, Hirata K, Sato T, Nakamura M, Kato K, Hirano H, Kumekawa Y, Hino K, Kawakami K, Kito Y, Matsumoto T, Kawakami T, Komoda M, Nagashima K, Sato Y, Yamazaki K, Hironaka S, Takaishi H, Hamamoto Y, Muro K. Shimozaki K, et al. Among authors: hirata k. Clin Colorectal Cancer. 2022 Dec;21(4):339-346. doi: 10.1016/j.clcc.2022.08.002. Epub 2022 Aug 12. Clin Colorectal Cancer. 2022. PMID: 36117091 Free article.
Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
Takahashi N, Hara H, Nagashima K, Hirata K, Masuishi T, Matsumoto T, Kawakami H, Yamazaki K, Hironaka S, Boku N, Muro K. Takahashi N, et al. Among authors: hirata k. BMC Cancer. 2023 Aug 5;23(1):726. doi: 10.1186/s12885-023-11199-1. BMC Cancer. 2023. PMID: 37543568 Free PMC article. Clinical Trial.
Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study.
Saito Y, Hamamoto Y, Hirata K, Yamasaki M, Watanabe M, Abe T, Tsubosa Y, Hamai Y, Murakami K, Bamba T, Yoshii T, Tsuda M, Watanabe M, Ueno M, Kitagawa Y. Saito Y, et al. Among authors: hirata k. BMC Cancer. 2023 Mar 28;23(1):283. doi: 10.1186/s12885-023-10710-y. BMC Cancer. 2023. PMID: 36978040 Free PMC article.
Biliary findings assist in predicting enlargement of intraductal papillary mucinous neoplasms of the pancreas.
Matsuzaki J, Suzuki H, Okuda S, Tanimoto A, Asakura K, Fukuhara S, Okada S, Hirata K, Mori H, Masaoka T, Higuchi H, Hozawa S, Kuribayashi S, Takebayashi T, Hibi T. Matsuzaki J, et al. Among authors: hirata k. Clin Gastroenterol Hepatol. 2013 May;11(5):548-54. doi: 10.1016/j.cgh.2012.11.027. Epub 2012 Dec 4. Clin Gastroenterol Hepatol. 2013. PMID: 23220169
4,262 results